These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2969435)

  • 1. Aminoglutethimide and ketoconazole: historical perspectives and future prospects.
    Shaw MA; Nicholls PJ; Smith HJ
    J Steroid Biochem; 1988 Jul; 31(1):137-46. PubMed ID: 2969435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer.
    Pérez N; Borja J
    J Int Med Res; 1992 Aug; 20(4):303-12. PubMed ID: 1387368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use of aromatase inhibitors in the treatment of breast cancers.
    Manni A
    J Cell Biochem Suppl; 1993; 17G():242-6. PubMed ID: 8007705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of aromatase inhibitors on estrogen 2-hydroxylase in rat liver.
    Purba HS; King EJ; Richert P; Bhatnagar AS
    J Steroid Biochem Mol Biol; 1994 Feb; 48(2-3):215-9. PubMed ID: 8142297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical use of aromatase inhibitors in human breast carcinoma.
    Santen RJ
    J Steroid Biochem Mol Biol; 1991; 40(1-3):247-53. PubMed ID: 1835644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent progress in development of aromatase inhibitors.
    Santen RJ
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1029-35. PubMed ID: 2149503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P450-dependent enzymes as targets for prostate cancer therapy.
    De Coster R; Wouters W; Bruynseels J
    J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro.
    Lamberts SW; Bruining HA; Marzouk H; Zuiderwijk J; Uitterlinden P; Blijd JJ; Hackeng WH; De Jong FH
    J Clin Endocrinol Metab; 1989 Oct; 69(4):896-901. PubMed ID: 2550511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of CGS 16949A. A new aromatase inhibitor.
    Lipton A; Harvey HA; Demers LM; Hanagan JR; Mulagha MT; Kochak GM; Fitzsimmons S; Sanders SI; Santen RJ
    Cancer; 1990 Mar; 65(6):1279-85. PubMed ID: 2137721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the aromatase inhibitor, rogletimide (pyridoglutethimide), on guinea pig adrenal cell steroidogenesis and placental microsomal aromatase activity: comparison with aminoglutethimide and CGS 16949A.
    Newton CJ; Mehta A; Dowsett M
    J Steroid Biochem Mol Biol; 1991 Nov; 39(5A):723-7. PubMed ID: 1659868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel aromatase inhibitors.
    Bhatnagar AS; Häusler A; Schieweck K; Browne LJ; Bowman R; Steele RE
    J Steroid Biochem Mol Biol; 1990 Nov; 37(3):363-7. PubMed ID: 2147860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo.
    Schieweck K; Bhatnagar AS; Matter A
    Cancer Res; 1988 Feb; 48(4):834-8. PubMed ID: 2962734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aromatase inhibitors in the treatment of advanced breast cancer.
    Miller WR
    Cancer Treat Rev; 1989 Jun; 16(2):83-93. PubMed ID: 2527597
    [No Abstract]   [Full Text] [Related]  

  • 14. Potency and specificity of CGS-16949A as an aromatase inhibitor.
    Santen RJ; Langecker P; Santner SJ; Sikka S; Rajfer J; Swerdloff R
    Endocr Res; 1990; 16(1):77-91. PubMed ID: 2139412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoglutethimide--a new endocrine therapy in breast cancer. A cancer research review.
    Harris AL
    Exp Cell Biol; 1985; 53(1):1-8. PubMed ID: 3881300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A.
    Steele RE; Mellor LB; Sawyer WK; Wasvary JM; Browne LJ
    Steroids; 1987; 50(1-3):147-61. PubMed ID: 2973160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of aromatase with CGS 16949A in postmenopausal women.
    Santen RJ; Demers LM; Adlercreutz H; Harvey H; Santner S; Sanders S; Lipton A
    J Clin Endocrinol Metab; 1989 Jan; 68(1):99-106. PubMed ID: 2521224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture.
    Yue W; Brodie AM
    J Steroid Biochem Mol Biol; 1997; 63(4-6):317-28. PubMed ID: 9459198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
    Santen RJ
    Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
    Santen RJ; Demers LM; Lynch J; Harvey H; Lipton A; Mulagha M; Hanagan J; Garber JE; Henderson IC; Navari RM
    J Clin Endocrinol Metab; 1991 Jul; 73(1):99-106. PubMed ID: 1646219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.